NanoENO Proof of Concept Project Develops Nano-scale Imaging Agent in Pre-clinical Development and Validation Based on Leti’s LipidotsTM Technology for Cancer Diagnosis
GRENOBLE, France – Dec. 5, 2014 – CEA-Leti and CLARA today announced the development of a new fluorescence-imaging agent that could significantly increase surgeons’ accuracy when removing cancerous tumors.
LipImage™ 815 was developed in the NanoENO project, which focused on producing a nano-scale contrast agent in the near infrared range for the resection of soft-tissue sarcomas, guided by imaging. This imaging agent is based on encapsulation of a fluorophore in Lipidots™. Lipidots™, Leti’s patented lipid nanovectors, are versatile nano-delivery platforms based on microscopic droplets of oil for encapsulating and carrying drugs or fluorescent imaging agents to targeted cells in the body for treatment or diagnosis.
The NanoENO project was coordinated by Leti and facilitated by the cancer-research cluster, Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), which fosters high-potential partnerships between academic, clinical and industrial organizations and companies from the Rhône-Alpes and Auvergne regions under its Proof of Concept program and industrial transfers.
During the project, preclinical validations were made on nine cases of resection of spontaneous soft-tissue sarcomas in pet-owners’ dogs, guided by fluorescence imaging after clinical scanner diagnosis. The clinical use confirmed the fluorescence of soft-tissue sarcomas, and helped surgeons visualize the tumoral extension to reach adequate surgical margins.
The project included the nuclear medicine department at the Hospital d'Orsay, the Veterinary School of Lyon (VetAgro Sup) and Advanced Accelerator Applications (AAA), a European pharmaceutical group spun out of CERN, in Geneva, Switzerland, in 2002 to develop innovative diagnostic and therapeutic products.
The contrast agent, developed in the NanoENO project, can be upgraded by grafting radio elements onto its surfaces to combine nuclear imaging for diagnostic purposes with intraoperative fluorescence imaging, into a single bimodal contrast agent.
“The NanoENO team clearly demonstrated that LipImage™ 815 is a very promising fluorescence-imaging agent for improving both diagnosis of disease and guiding surgeons during tumor removal,” said Patrick Boisseau, head of Leti’s nanomedicine program and chairman of the European Technology Platform – Nanomedicine (ETPN). “This surgical application also shows the versatility of Leti’s Lipidots™ technology, which is already being adapted for medical diagnosis and cosmetics purposes by Leti partners.”
“For nearly 11 years, Cancéropôle CLARA has actively supported leading-edge clinical oncology research that capitalizes on the regions’ rich technological and medical expertise, and we have fostered transfer of the results to industry through our system of public-private partnerships,” said Dr. Amaury Martin, secretary general of CLARA. “The NanoENO project success strongly validates the mission of CLARA’s Proof of Concept program.”
The €700,000 project included funding from FEDER Rhône-Alpes and Région Rhône-Alpes, the European Fund for Economic and Regional Development and Advanced Accelerator Applications (AAA).
About CEA-Leti (France)
By creating innovation and transferring it to industry, Leti is the bridge between basic research and production of micro- and nanotechnologies that improve the lives of people around the world. Backed by its portfolio of 2,200 patents, Leti partners with large industrials, SMEs and startups to tailor advanced solutions that strengthen their competitive positions. It has launched more than 50 startups. Its 8,000m² of new-generation cleanroom space feature 200mm and 300mm wafer processing of micro and nano solutions for applications ranging from space to smart devices. Leti’s staff of more than 1,700 includes 200 assignees from partner companies. Leti is based in Grenoble, France, and has offices in Silicon Valley, Calif., and Tokyo. Follow us on www.leti.fr and .@CEA_Leti.
About Lyon Rhône-Alpes Auvergne Cancer Research Cluster (CLARA)
CLARA was initiated and is funded by public authorities as a result of the French National Cancer Plan. The research cluster aims to develop oncology research in Rhône-Alps and Auvergne by associating academic, clinical and industrial partners of both regions in order to develop a regional, national and international strategy in the fight against cancer. CLARA contributes to the implementation of partnerships between industrials and academic and clinical research laboratories to foster technological transfers for the benefit of patients. CLARA’s ambition is to position the Rhône-Alps Auvergne inter-region among the European reference in the fight against cancer. For more information about Proof of Concept, please visit http://www.canceropole-clara.com/appels-a-projet/preuve-du-concept-clara/
About Advanced Accelerator Applications (AAA)
Advanced Accelerator Applications is a radiopharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (“Personalized Medicine”). AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S. and Canada). In 2013 AAA reported sales of €53.8 million (+31.77% vs. 2012). For more information please visit: www.adacap.com
Press contacts
CEA-Leti | Pierre-Damien Berger
+33 4 38 78 02 26
Agency | Sarah Lyle Dampoux
+33 6 74 93 23 47
CLARA | Justine MONET
+33 6 60 82 06 88